Navigation Links
Novel therapeutic agents provide hope for patients with hard-to-treat blood disorders
Date:12/9/2012

Phase I/II study and administered an oral dose of the proteasome inhibitor combined with lenalidomide and dexamethasone for up to 12, 28-day cycles, followed by maintenance therapy with MLN9708 every 28 days until disease progression. Primary objectives in Phase I included safety, maximum tolerated dose, and recommended Phase II dose. In Phase II, primary objectives included complete remission and very good partial response (VGPR, measured by a 90% or greater reduction in abnormal myeloma proteins in the blood).

In Phase I, the maximum tolerated dose was determined as 2.97 mg/m2 and recommended Phase II dose was selected as 2.23 mg/m2, which was later converted to a 4.0 mg/m2 dose based on encouraging results related to the body's ability to tolerate the drug. In Phase II, the investigators observed an overall response rate of 92 percent with 55 percent of patients reaching VGPR or better, including 23 percent with a complete remission. As the treatment cycles progressed, the rate and depth of response increased.

Minor adverse events, such as fatigue, nausea, and rash, were noted in approximately 40 percent of patients. Serious adverse events were minimal and primarily consisted of decreased blood counts, nausea and vomiting, diarrhea, rash, and electrolyte disturbances. One patient died from pneumonia while on treatment, and seven patients discontinued treatment due to different side effects.

"As targeted therapies continue to evolve, we are now shifting our efforts to focus on making them safer and producing them in more convenient forms for patients. MLN9708 is a great example of how to accomplish this goal," said Shaji K. Kumar, MD, lead author and Professor of Medicine and Consultant in Hematology at the Mayo Clinic in Rochester, Minn. "We are now planning ongoing studies to examine this drug in combination with other myeloma drugs in Phase II and Phase III clinical trials. Once approved for treatment of myeloma, this drug will al
'/>"/>

Contact: Andrea Slesinski
aslesinski@hematology.org
614-352-5096
American Society of Hematology
Source:Eurekalert

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Researchers develop novel 3-D culture system for inflammatory breast cancer
2. ACNP: Novel NMDA receptor modulator significantly reduces depression scores within hours
3. Scripps Florida scientists uncover a novel cooperative effort to stop cancer spread
4. Novel mechanism through which normal stromal cells become cancer-promoting cells identified
5. Novel breast screening technology increases diagnostic accuracy
6. UNC, Vanderbilt discover a new live vaccine approach for SARS and novel coronaviruses
7. Moffitt Cancer Center researchers identify novel metabolic programs driving aggressive brain tumors
8. Novel treatment strategies for epilepsy
9. Taiho Pharmaceutical unveils data on 8 novel anticancer compounds
10. Researchers ID potential patient population who may benefit from novel anti-platelet treatment
11. Undertreatment of common heart condition persists despite rapid adoption of novel therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2014)... C8 lawsuits move forward in the U.S. District ... 20 possible C8 lawsuits selected for bellwether trials ... & Schulte LLC. Court records show these six C8 ... filed that represent individuals who purportedly developed kidney cancer, ... being exposed to water contaminated by the C8 chemical ...
(Date:9/21/2014)... 21, 2014 Top10BestSEOHosting.com, a leading ... ) and GreenGeeks are the most recommended hosting ... buy high quality hosting products. , “Don’t ... suppliers; we recommend two great hosting companies to ... believe that iPage and GreenGeeks are the most ...
(Date:9/20/2014)... 21, 2014 Recently, UWDress.com, a professional ... a promotion for its newly announced evening cocktail ... the company’s special occasion outfits are very popular among ... provided with big savings (up to 65 percent off). ... offer more fashionable special occasion outfits for the global ...
(Date:9/20/2014)... 2014 Weight Destroyer , a ... expert Michael Wren that has already helped tens of ... health conditions like high blood pressure, high cholesterol, and ... prompting an investigative review. , “Weight Destroyer is ... down by showing people what is truly effective when ...
(Date:9/20/2014)... 20, 2014 David Cooke presented two ... first poster looked at the clinical benefits of MPI ... calculating diastolic function. In conjunction with colleagues at Emory ... and normal LVEF by echo (>50%). Each patient had ... standard SPECT. Emory Toolbox 4.0 was used ...
Breaking Medicine News(10 mins):Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 2Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 3Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 4Health News:Leading Review Website Top10BestSEOHosting.com Unveils The Best Hosting Suppliers In September 2Health News:Cheap Evening Cocktail Dresses Recently Introduced At UWDress.com 2Health News:Weight Destroyer: Review Exposes Michael Wren’s Guide to Effective Weight Loss and Improved Health 2Health News:Weight Destroyer: Review Exposes Michael Wren’s Guide to Effective Weight Loss and Improved Health 3Health News:Versatility of Emory Toolbox 4.0 Shown at ASNC in Scientific Posters 2Health News:Versatility of Emory Toolbox 4.0 Shown at ASNC in Scientific Posters 3
... rates reach the highest levels in 16 years, a ... laid-off workersonly 9 percenttook up coverage under the Consolidated ... who also lose their health insurance would need substantial ... health insurance premiums, for their premium contributions to remain ...
... Incidents were reported by half of family caretakers surveyed in ... than half of family members looking after people with dementia ... British study finds. , Actual physical abuse was rare, being ... study. But the researchers, who published their findings in ...
... 22 The following is a statement from United ... Hearing Officer Ray Marshall ruled against a ... of the Service Employees International Union in 1921 that ... right to take over a local union. Even with ...
... T. Allison, FACHE, president/CEO of Baylor Health Care System ... the Texas Hospital Association,s Earl M. Collier Award for ... Award is the highest honor bestowed by THA. Allison ... Leadership Conference in Austin."Joel Allison exemplifies the leadership qualities ...
... MADISON, N.J., Jan. 22 At a meeting of its ... ) declared dividends on both the Common and Preferred Stock ... on the outstanding shares of Common Stock was declared payable ... close of business on February 13, 2009. In addition, ...
... WASHINGTON, Jan. 22 Speaker Nancy Pelosi released ... 36th Anniversary of Roe v. Wade:"On the 36th ... commitment to protecting a woman,s right to make ... just two days after swearing in a new ...
Cached Medicine News:Health News:Only about one of ten unemployed workers obtain COBRA coverage 2Health News:Many Alzheimer's Caregivers Admit to Abusive Behavior 2Health News:Many Alzheimer's Caregivers Admit to Abusive Behavior 3Health News:UHW Statement on Ray Marshall Trusteeship Recommendations 2Health News:Allison Honored with Hospital Association's Highest Award 2Health News:Allison Honored with Hospital Association's Highest Award 3
(Date:9/19/2014)... 19, 2014 The Parenteral Drug Association (PDA) ... post-approval changes protocols. The new initiative ... expressed by industry participants and regulatory authority representatives at ... in Washington, DC . Representatives of ... for the workshop. Attendees indicated openness to engaging regulators ...
(Date:9/19/2014)... Research and Markets ... of the "Global Gynecological Devices Market ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... wide categories based on their operations. These ... different gynecological conditions that affect the female ...
(Date:9/19/2014)... RESEARCH TRIANGLE PARK, N.C. , Sept. 19, ... company focused on cloud-based drug design and development, ... strategy. The company,s mission is to design new ... Phase 1 and 2 partners to further their ... enhance its portfolio investments. To support this business ...
Breaking Medicine Technology:PDA Launches Effort to Harmonize Global Post-Approval Changes Protocols 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 3Cloud Pharmaceuticals Announces Partnering Sessions and Presentation Schedule 2
... NEW YORK, Dec. 8, 2010 Reportlinker.com announces that ... catalogue: China Pharmaceutical Market Overview ... IntroductionThe Chinese hospital prescription pharma market generated sales of ... of 26.5% between 2008 and 2009. Key growth drivers ...
... Reportlinker.com announces that a new market research ... Russia Pharmaceutical Market Overview Pharma ... presents http://www.reportlinker.com/p0337454/Russia-Pharmaceutical-Market-Overview---Pharma-companies-target-Russia-despite-the-challenges-it-presents.html ... generated $10.1 billion in sales in 2009, ...
Cached Medicine Technology:Reportlinker Adds China Pharmaceutical Market Overview 2Reportlinker Adds China Pharmaceutical Market Overview 3Reportlinker Adds China Pharmaceutical Market Overview 4Reportlinker Adds China Pharmaceutical Market Overview 5Reportlinker Adds China Pharmaceutical Market Overview 6Reportlinker Adds China Pharmaceutical Market Overview 7Reportlinker Adds China Pharmaceutical Market Overview 8Reportlinker Adds China Pharmaceutical Market Overview 9Reportlinker Adds China Pharmaceutical Market Overview 10Reportlinker Adds China Pharmaceutical Market Overview 11Reportlinker Adds China Pharmaceutical Market Overview 12Reportlinker Adds China Pharmaceutical Market Overview 13Reportlinker Adds China Pharmaceutical Market Overview 14Reportlinker Adds China Pharmaceutical Market Overview 15Reportlinker Adds China Pharmaceutical Market Overview 16Reportlinker Adds China Pharmaceutical Market Overview 17Reportlinker Adds Russia Pharmaceutical Market Overview Pharma Companies Target Russia Despite the Challenges it Presents 2Reportlinker Adds Russia Pharmaceutical Market Overview Pharma Companies Target Russia Despite the Challenges it Presents 3Reportlinker Adds Russia Pharmaceutical Market Overview Pharma Companies Target Russia Despite the Challenges it Presents 4Reportlinker Adds Russia Pharmaceutical Market Overview Pharma Companies Target Russia Despite the Challenges it Presents 5Reportlinker Adds Russia Pharmaceutical Market Overview Pharma Companies Target Russia Despite the Challenges it Presents 6Reportlinker Adds Russia Pharmaceutical Market Overview Pharma Companies Target Russia Despite the Challenges it Presents 7Reportlinker Adds Russia Pharmaceutical Market Overview Pharma Companies Target Russia Despite the Challenges it Presents 8Reportlinker Adds Russia Pharmaceutical Market Overview Pharma Companies Target Russia Despite the Challenges it Presents 9Reportlinker Adds Russia Pharmaceutical Market Overview Pharma Companies Target Russia Despite the Challenges it Presents 10Reportlinker Adds Russia Pharmaceutical Market Overview Pharma Companies Target Russia Despite the Challenges it Presents 11Reportlinker Adds Russia Pharmaceutical Market Overview Pharma Companies Target Russia Despite the Challenges it Presents 12Reportlinker Adds Russia Pharmaceutical Market Overview Pharma Companies Target Russia Despite the Challenges it Presents 13Reportlinker Adds Russia Pharmaceutical Market Overview Pharma Companies Target Russia Despite the Challenges it Presents 14
5 mm tying platform, serrated cross action handle with polished finish. Teeth: 0.10 mm, 1 x 2 set at 90 degrees....
5 mm tying platform, serrated cross action handle with polished finish. Teeth: 0.10 mm, 1 x 2 set at 45 degrees....
6 mm tying platform. Round knurled handle with polished finish. Teeth: 0.3 mm, 1 x 2. Orientation: Left hand....
0.12 mm, 1 x 2 teeth set at 45 degrees with 6 mm tying platform. Wide serrated handle with polished finish....
Medicine Products: